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In recent years, scientific and technological advancements have been made in the
research and development of controlled release oral drug delivery systems by overcom-
ing the physiologically unpredictable gastric emptying time. Oral dosage forms for gas-
tric retention have drawn more attention for their theoretical advantage in permitting
control over the time and site of drug release (1, 2). Prolonged gastric retention would be
particularly valuable for drugs that are unstable in lower parts of the gastrointestinal
tract and poorly soluble at high pH values (3). In addition, prolonged gastric retention
of the therapeutic moiety may offer numerous advantages, including improved bioavaila-
bility and therapeutic efficacy and possible reduction of dose size (4, 5).
A floating drug delivery system is a type of gastro retentive dosage form able to
prolong gastric retention to obtain sufficient drug bioavailability. Floating systems are
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Floating dosage forms of acetylsalicylic acid, used for its
antithrombotic effect, were developed to prolong gastric
residence time and increase bioavailability. In the two-la-
yer tablet formulation, hydroxypropyl methylcellulose
(HPMC) of high viscosity and an effervescent mixture of
citric acid and sodium bicarbonate formed the floating la-
yer. The release layer contained the drug, direct tableting
agent and different types of matrix-forming polymers such
as HPMC of low viscosity, sodium carboxymethylcellu-
lose and chitosan. Tablets were prepared using a direct
compression technique. The effect of formulation varia-
bles on physicochemical and floating properties and the
drug release from tablets were investigated. Floating abi-
lity was dependent on the amount of effervescent agent
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lease was prolonged to 8 hours by changing the type and
viscosity of the matrix-forming polymer in the drug-loa-
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se mechanisms.
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classified by two distinctly different technologies, depending on the mechanism of buo-
yancy: effervescent and non-effervescent systems (2, 6, 7). Effervescent floating dosage
forms, which are matrix systems, are prepared with swellable polymers such as HPMC
or chitosan and with an effervescent mixture of citric acid and sodium bicarbonate as a
gas-generating agent (8, 9). Non-effervescent systems are prepared with gel-forming, hi-
ghly swellable hydrocolloids and polymers. Floating chambers may also be added to the
formulations to provide floating (2, 10). In this study, effervescent floating dosage forms
were studied.
Polymer properties and type play an important role in the pattern and rate of drug
release and floating behaviors in the floating system. Özdemir et al. (11) developed a float-
ing bilayer tablet containing furosemide using HPMC as the rate-controlling polymeric
excipient. Radiographic studies on 6 healthy male volunteers revealed that floating tab-
lets were retained in the stomach for 6 hours and further blood analysis studies showed
that bioavailability of these tablets was 1.8 times that of conventional tablets. Baumgar-
tner et al. (5) developed a matrix-floating tablet incorporating a high dose of freely solu-
ble drug. The formulation containing 54.7 % of the drug, HPMC K4 M, Avicel pH 101,
and a gas-generating agent gave the best results. It took 30 seconds to become buoyant.
In vivo experiments with fasted beagle dogs revealed prolonged gastric residence time.
The objective of the present study was to develop a new floating two-layer tablet
formulation that has a bulk density lower than that of gastric fluids and remains buoy-
ant in the stomach. To achieve this objective, the contribution of several formulation va-
riables on the drug release rate and floating properties of the gastric floating drug deliv-
ery system were examined. Acetylsalicylic acid (ASA), which has been widely utilized
for treatment of cardiovascular disorders for its antithrombotic effect, was used as the
model drug in this formulation.
EXPERIMENTAL
Materials
Acetylsalicylic acid (Bayer, Germany), hydroxypropyl methylcellulose of high vis-
cosity (HPMC, 4000 cP) (Fluka, Switzerland), hydroxypropyl methylcellulose of low vis-
cosity (HPMC, 100 cP) (Sigma, USA), sodium carboxymethylcellulose (NaCMC, medium
viscosity) (Sigma), chitosan of different molecular mass [low, medium and high (LMW,
MMW, HMW), degree of deacetylation of min. 75 %] (Aldrich, Germany), Di-Pac® (Am-
star Corporation, USA), citric acid monohydrate (Aklar Chemistry, Turkey) and sodium
bicarbonate (Aklar Chemistry) were used in the study. All other chemicals used were of
reagent grade.
Methods
Preparation of floating two-layer tablets. – Formulations were prepared as two-layered
tablets. One of the layers contained an effervescent mixture of citric acid and sodium bi-
carbonate as a gas-generating agent and HPMC 4000 as a matrix material to retain the
air bubbles produced in the tablets. The other layer provided modified release of the
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drug and comprised 100 mg ASA and various polymers such as HPMC 100, NaCMC or
chitosan of different molecular mass as a retarding agent, and Di-Pac® as a direct tab-
leting agent. The tablet formulations are shown in Table I. The components of each layer
were blended homogeneously for 15 min in a mortar. Preparation of the two-layer tablet
had two steps. At the beginning, the floating layer was placed in the die cavity and pre-
paratory pressing was applied. Thereafter, the release layer was added and the final tab-
lets were compressed using a single tableting hand press with a 12-mm flat-faced punch.
Floating behavior of tablets. – In vitro floating behavior of the tablets was tested using
the paddle method (USP 24 apparatus II) containing 900 mL of simulated gastric fluid
(12) (SGF) without enzyme, pH 1.2, with paddle rotation of 50 rpm at 37 ± 0.5 °C. The
following parameters were determined: the time needed to float on the surface (floating
lag time) and floating duration.
In vitro drug release. – Dissolution experiments were used to evaluate the in vitro
drug release of the tablets. These studies were carried out using the paddle method at a
paddle speed of 50 rpm in 900 mL of SGF at 37 ± 0.5 °C for 8 h. At predetermined time
intervals, a sample was withdrawn from the dissolution vessel. To maintain a constant vo-
lume, fresh SGF was added to the dissolution vessel after each withdrawal. The amount
of drug released was assayed with a UV-visible spectrophotometer (Shimadzu UV-1202,
Japan) at a wavelength of 247 nm. Each in vitro release study was performed in tripli-
cate. The data obtained from the dissolution tests were analyzed statistically using the
simple analysis of variance (one-way ANOVA) or independent-sample t-test.
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Table I. Formulation of floating tablets containing ASA
Composition (mg) Formulation code
Release layer F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13
ASA 100 100 100 100 100 100 100 100 100 100 100 100 100
HPMC 100 cP 50 50 50 50 30 90 50 – – – – – –
NaCMC – – – – – – – 50 – – – – –
Chitosan (LMW) – – – – – – – – 50 – – 75 –
Chitosan (MMW) – – – – – – – – – 50 – – 75
Chitosan (HMW) – – – – – – – – – – 50 – –
Di-Pac® 20 20 20 20 20 20 20 20 20 20 20 20 20
ASA (%) 58.8 58.8 58.8 58.8 66.7 47.6 58.8 58.8 58.8 58.8 58.8 51.3 51.3
Floating layer
HPMC 4000 cP 250 250 250 250 250 250 125 250 250 250 250 250 250
Sodium bicarbonate 17 34 51 68 34 34 34 34 34 34 34 34 34
Citric acid
monohydrate
14 28 42 56 28 28 28 28 28 28 28 28 28
Total mass 281 312 343 374 312 312 187 312 312 312 312 312 312
Kinetic assessment of dissolution data. – The dissolution rate data obtained were evalua-
ted for compatibility with the kinetics of zero order, Higuchi equation (13) (Eq. 1), Kors-
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where Mt/M is the fraction of drug released after time t relative to the amount of drug
released at infinite time, k and ký are kinetic constants characteristic of the drug/ poly-
mer system, n is the release exponent that depends on the release mechanism and the
shape of the matrix tested, k1 and k2 are the kinetic constants for the diffusional and re-
laxation drug dissolution, respectively, m is the purely Fickian diffusion exponent for a
device of any geometrical shape that exhibits controlled release.
RESULTS AND DISCUSSION
Characterization of floating two-layer tablets
Two-layer tablet formulations were successfully prepared using a direct compres-
sion method. Physical properties of the tablets are shown in Table II. The thickness of all
tablet batches ranged from 3.7 ± 0.1 to 4.4 ± 0.1 mm and the diameter of all tablets was
12 mm. The mass of the tablets ranged from 355.5 ± 0.5 to 543.5 ± 0.6 mg due to the dif-
ferences in formulation design. Drug content was found to be consistent and uniform in
all tablet formulations.
Floating two-layer tablet formulations were prepared using an effervescent approach.
The first layer provided the floatation, accomplished by incorporating a gas-forming agent
dispersed into HPMC 4000 as a swellable hydrophilic matrix to retain the air bubbles.
HPMC 4000 was also chosen as a low-density hydrocolloid system. On contact, the simu-
lated gastric medium reacted with the effervescent mixture in the floating layer of the
two-layer tablet. It was observed that the gas generated was trapped in and protected by
the gel formed HPMC.
Ideally, the floating system should float a few minutes after contact with the gastric
fluid to prevent the dosage forms transiting into the small intestine (7, 16). Therefore, the
floating layer formulations were optimized to obtain the shortest lag time and to pro-
long the gastro retention time. We prepared F1, F2, F3, F4 and F7 coded formulations,
which included different concentrations of sodium bicarbonate and citric acid as
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gas-generating agents and HPMC 4000 in the floating section, without changing the re-
lease layer. When the concentration of the effervescent mixture increased in the floating
layer, the tablets were found to exhibit short floating lag time due to faster and higher
CO2 generation. However, tablet integrity decreased with a larger amount of efferves-
cent mixture in the floating layer. Moreover, the formulations containing lower efferves-
cent mixture did not float because of the lower efficiency of the gas forming agent.
By using HPMC 4000, significant and stable, persistent buoyancy was obtained. Re-
duction of the concentration of HPMC 4000 in the floating layer reduced the floating lag
time, but decreased tablet integrity due to the lack of HPMC 4000 to restrain the gas-
-bubbles. Therefore, the amount of the effervescent mixture was chosen for the shortest
possible lag time and floating duration of up to 8 h. The optimized floating layer formu-
lation, coded as F2, had a floating lag time of 2.8 min, good matrix integrity and floating
duration of more than 8 h (Table II). It is well known that the compression force strongly
effects the lag time of floating (11, 17). Two different F2 formulations were pressed at
pressures of 16 and 32 MPa. However, the F2 formulation produced at 16 was found to
have better floating behavior. When the compression force was increased from 16 to 32
MPa, it was observed that the onset of floating increased from 3 to 18 min. The tablets
compressed at a lower pressure retained a higher trapped air concentration, which re-
sulted in decreasing the agglomerate density and allowing floating of the tablets. On the
other hand, the tablets compressed at higher pressure were found to be less porous with
high density preventing the tablets to float. Thus, a compression force of 16 MPa was
adopted in the pressing of all tablet formulations. The final floating two-layer tablet for-
mulations were prepared, containing the optimized floating layer and the release layer
comprising ASA, Di-Pac® and various polymers. Di-Pac® was used in these formulations
as a direct tableting agent in the drug-loading layer to compress the tablets more easily.
It was also reported that hydrophilic substances such as Di-Pac® enhanced the water up-
take of matrix tablets (11).
In vitro drug release
Before the dissolution test of formulations, the dissolution profile of pure ASA was
determined in a simulated gastric environment. It was seen that the dissolution rate of
the drug was quite fast and more than 80 % of the drug released within 15 min (Fig. 1).
Design of the release layer may require different types and amounts of polymers to ob-
tain floating tablets with desirable properties. The polymer properties used in this layer
are an important factor in modifying the drug release. Therefore, the effect of several
polymers such as HPMC 100, NaCMC and chitosan on the release profiles of the drug
from the tablets was examined. All polymers were used as matrix-gel forming agents
that hydrate and form a gelatinous barrier. As shown in Figs 1a and b, they exhibited
substantial decrease in the drug release rate.
The F8 coded tablet formulation containing NaCMC in the drug-loaded layer quickly
gelled and lost shape. Floatation began within 4.2 min upon contact with the gastric me-
dium and floated for 4 h, but then the drug-loaded section separated from the floating
section. The release profiles appear to be bi-phasic with an initial burst effect followed
by a polymer-controlled slower release in the second phase (Fig. 1a). However, NaCMC
as a polymer in the release layer produced inadequate drug release where the release
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could not be controlled for a long time, possibly because of the poor strength of the ma-
trix. Approximately 80 % of the drug from the tablet was released within 2 h.
F2, F5 and F6 formulations containing different concentrations of HPMC 100 in the
drug-loaded layer had the floating lag time below 5.3 min (Table II). The flotation and
floating lag time did not change significantly by increasing the amount of polymer in
the drug release layer. All tablets had to float on the dissolution medium for more than
12 h. Fig. 1a shows the dissolution profiles of ASA from the prepared tablets containing
HPMC 100 at various concentrations. The data indicates that the presence of HPMC 100
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F1 22.2 449.1 ± 0.7 99.3 ± 1.7 3.8 ± 0.1 Eroded – –
F2 20.8 479.3 ± 0.5 97.2 ± 0.8 4.2 ± 0.1 Good 2.8 ± 0.1 > 12
F3 19.5 511.7 ± 0.9 99.3 ± 0.9 4.1 ± 0.1 Eroded – –
F4 18.4 543.5 ± 0.6 101.2 ± 0.4 4.2 ± 0.1 Eroded – –
F5 21.6 462.3 ± 0.4 99.8 ± 1.7 3.4 ± 0.1 Good 2.7 ± 0.8 > 12
F6 19.2 532.4 ± 0.6 100.1 ± 1.1 4.3 ± 0.1 Good 5.3 ± 1.7 > 12
F7 28.0 355.5 ± 0.5 99.9 ± 1.4 2.8 ± 0.1 Eroded 0.5 ± 0.01 –
F8 20.8 481.5 ± 0.5 99.2 ± 0.6 3.5 ± 0.1
Eroded
after 4 h 4.2 ± 0.9
4
F9 20.8 480.4 ± 0.4 100.2 ± 1.9 3.8 ± 0.1 Good 9.7 ± 2.0 > 12
F10 20.8 484.6 ± 0.5 99.3 ± 1.7 3.7 ± 0.7 Good 11.3 ± 1.2 > 12
F11 20.8 475.2 ± 0.6 101.5 ± 1.0 3.8 ± 0.1 Good 9.7 ± 1.7 > 12
F12 19.7 505.3 ± 0.5 99.1 ± 0.8 4.2 ± 0.1 Good 9.0 ± 1.9 > 12
F13 19.7 509.6 ± 0.5 100.9 ± 1.2 4.1 ± 0.1 Good 10.0 ± 1.5 > 12
a Concentration of ASA in the whole tablet.




















































Fig. 1. Release profiles of ASA from the two-layer floating tablets using: a) NaCMC and HPMC 100,
b) chitosan with different properties (mean ± SD, n = 3).
had a significant effect on the release of the delivery system. As expected, there is a clear
difference in the ASA release pattern between the polymers in different concentrations
(p < 0.05). A decrease in the release rate was observed with an increase in the amount of
the polymer in the release layer. Similar results were reported by Colombo et al. (18),
who reported that increased viscosity resulted in a corresponding decrease in the drug
release rate. The effect of the polymer concentration is connected with increased viscos-
ity and the length of the dissolution path through the matrix. For formulations F2, F5
and F6, drug release was 87 %, 68 % and 51 %, respectively, within 8 h. All formulations
were able to keep their integrity during the dissolution test and therefore showed good
control of the drug release, with slower release rate for a desired period of time. In addi-
tion, it was observed that adding the HPMC as a polymer to the release layer decreased
the drug release rate and resulted in linearization of the drug release curves. The release
rate constants obtained from Higuchi kinetics for tablets coded F5 (containing 66.7 %
ASA), F2 (containing 58.8 % ASA) and F6 (containing 47.6 % ASA) were found to be
4.245, 3.189 and 2.360 min–1/2 respectively (Table III); these values indicated that the drug
release was enhanced with increasing the drug concentration. A linear correlation (R2 =
0.972) was also found between these values.
In the release layer, different molecular mass chitosans (HMW, MMW, LMW chi-
tosan) and concentrations of chitosan were used to optimize drug release and floating
properties (Table I). None of the formulations containing chitosan showed a significant
effect on the floating lag time and floatation period. All tablet formulations began float-
ing approximately 10 min after immersion into the release medium and floated until the
end of the dissolution test. It was also noted that the tablets remained intact during drug
release. The release profiles of formulations coded F9, F10, F11, F12 and F13, prepared
by using chitosan, are illustrated in Fig. 1b. When chitosan was added to the drug-loa-
ded layer, the drug release rate decreased dramatically. Significant differences were ob-
served between dissolution profiles (p < 0.05) of formulations prepared by using chitosan
(F9-F13). The results showed that the molecular mass of chitosan played an important
role in the design of the drug release layer. Comparing drug release rates among the dif-
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Table III. Kinetic assessment of release data obtained from two-layer floating tablet formulations prepared






F2 F5 F6 F8 F9 F10 F11 F12 F13
Zero-order
k0 (mg min–1) 0.125 0.159 0.086 0.388 0.412 0.231 0.198 0.362 0.299
R2 0.914 0.872 0.903 0.847 0.975 0.939 0.969 0.973 0.983
Higuchi
k (min–1/2) 3.189 4.245 2.360 6.367 5.831 4.797 3.686 5.214 4.392
R2 0.998 0.996 0.995 0.966 0.980 0.993 0.988 0.959 0.930
Korsmeyer-
Peppas





















R2 = determination coefficient, n = release exponent
ferent tablet formulations, it was evident that formulation F9, which contained LMW
chitosan, exhibited the highest drug release rate. On the other hand, formulations F10
and F11, prepared with MMW and HMW chitosan, respectively, exhibited slower release
rates. The slowest release rates were observed for formulations containing HMW chito-
san, as a result of its high viscosity. As seen in Fig. 1b, the dissolution rate of the drug
did not change effectively by increasing the chitosan concentration.
Kinetic assessment of dissolution data
Zero-order kinetics, Higuchi equation and Korsmeyer-Peppas and Peppas-Sahlin mo-
dels were used to determine the drug release kinetics (13-15). Kinetic assessments of the
dissolution data are shown in Tables III and IV. In all formulations containing NaCMC
and HPMC 100 in the release layer, the Higuchi equation was found to be efficient in de-
scribing the kinetics of drug release, with drug release proportional to the square root of
time, due to the hydrophilic structure of the matrix. It has been suggested that the ero-
sion mechanism, in addition to diffusion, was influential on the release of active mate-
rial. To explore the release pattern, results of the in vitro release data of the formulations
were also fitted to the Korsmeyer-Peppas equation, which characterizes the transport me-
chanism based on the values of n (14). For the matrix tablet, when n takes the value of
0.45, it indicates diffusion-controlled drug release whill for the value 0.89, it indicates
swelling-controlled release. Values of n between the two values can be regarded as indi-
cators of anomalous transport (19). All formulations exhibited values close to 0.45, indi-
cating that the drug release was governed by Fickian diffusion. However, increasing the
polymer content increased the exponent n (Table III). This is attributed to an increasing
restriction of drug release produced by increasing polymer viscosity. The formulations
containing a low concentration of chitosan (LMW, MMW and HMW) fitted well to the
Higuchi equation, indicating a diffusion mechanism. When the concentration of chito-
san in the formulation was increased, n increased from 0.600 to 0.925, characterizing the
anomalous transport release mechanism, and the release mechanism was close to zero-
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Table IV. Parameter estimates derived from Peppas-Sahlin equation to experimental data





































k1 – kinetic constant for diffusional drug dissolution, k2 – kinetic constant for relaxation drug dissolution;
m – purely Fickian diffusion exponent for a device of any geometrical shape that exhibits controlled release
-order. According to the Peppas and Sahlin equation, the derived k2 values that repre-
sent case-II transport (erosion mechanism) were found much lower than k1 (Table IV). It
was concluded that diffusion was the predominant mechanism of drug release in all for-
mulations.
CONCLUSIONS
In this study, we developed a two-layer floating oral drug delivery system with de-
sired release profiles and floating properties. Stable and persistent buoyancy was achie-
ved by trapping the gas in the gel formed by the hydration of HPMC 4000. Gas forma-
tion was obtained from an effervescent mixture of sodium bicarbonate and citric acid.
The release of the drug from the release layer prepared with various types of polymers
revealed different behaviors. Tablets including HPMC 100 showed the slowest release
pattern. The release rate could effectively be modified by using HPMC 100 and chitosan
for a modified release of 8 h, following the Higuchi diffusion mechanism. The drug re-
lease patterns can be effectively adjusted by varying simple formulation parameters, such
as the type and viscosity of matrix-forming polymers.
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S A @ E T A K
U~inak formulacijskih parametara na osloba|anje lijeka
i svojstva dvoslojnih tableta koje plutaju u `elucu
CANAN HASÇIÇEK, GÜNSELI YÜKSEL-TILKAN, BERNA TÜRKMEN i NURTEN ÖZDEMIR
U radu su opisane plutaju}e tablete acetilsalicilne kiseline za antikoagulacijsku upo-
trebu s produljenim zadr`avanjem u `elucu i ve}om bioraspolo`ivo{}u. Plutaju}i dio tih
dvoslojnih tableta sadr`avao je hidroksipropil metilcelulozu (HPMC) visoke viskoznosti
i efervescentnu smjesu limunske kiseline i natrijevog hidrogenkarbonata. Drugi sloj sadr-
`avao je ljekovitu tvar, sredstvo za izravno tabletiranje i razli~ite vrste matriksnog po-
limera poput HPMC niske viskoznosti, natrijeve soli karboksimetilceluloze i kitozana.
Tablete su pripravljene metodom izravne kompresije. Ispitivan je utjecaj formulacijskih
varijabli na fizikokemijska i plutaju}a svojstva, te osloba|anje ljekovite tvari. Plutaju}a
svojstva ovise o koli~ini efervescentnih tvari i geliraju}eg polimera u plutaju}em sloju.
Promjenom vrste i viskoznosti polimera u matriksnom sloju s lijekom produljeno je oslo-
ba|anje ljekovite tvari na 8 sati. Iz svih formulacija ljekovita tvar osloba|ala se difuzijom.
Klju~ne rije~i: dvoslojne plutaju}e tablete, zadr`avanje u `elucu, hidroksipropil metilceluloza, kitozan
Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06100-Tandogan,
Ankara, Turkey
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